SequelSEC

Vicapsys Life Sciences, Inc. VICP

Pharmaceutical Preparations · CIK 0001468639 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2023-12-31
Operating income
-$1.05M
Fiscal year ended 2023-12-31
Free cash flow
Unavailable
Fiscal year ended 2023-12-31

Vicapsys Life Sciences, Inc. (VICP) reported net income of -$1.18M for the fiscal year ended 2023-12-31. This page shows 5 annual periods of income statement, balance sheet and cash flow figures normalized from Vicapsys Life Sciences, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Vicapsys Life Sciences, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2023-12-312022-12-312021-12-312020-12-312019-12-31
RevenueUnavailableUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$1.05M-$984.79K-$336.87K-$765.84KUnavailable
Net income-$1.18M-$984.79K-$236.87K-$765.84K-$1.41M
Research & development$15.27K$13.10K$17.70K$102.18K$98.98K
Weighted-average diluted sharesshares 34.55Mshares 30.58MUnavailableUnavailableUnavailable
Pretax income-$1.18M-$984.79K-$236.87K-$765.84K-$1.03M
Income tax expenseUnavailableUnavailableUnavailableUnavailableUnavailable
Diluted EPS$-0.03$-0.03UnavailableUnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$96.43K$60.20K$35.79K$46.96K$54.11K
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Vicapsys Life Sciences, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2023-12-312022-12-312021-12-312020-12-312019-12-31
Cash & equivalents$9.42K$14.10K$217.30K$1.27K$264.17K
Total assets$39.66K$72.02K$594.31K$404.12K$698.44K
Current assets$39.66K$72.02K$222.79K$1.27K$264.17K
Total liabilitiesUnavailableUnavailableUnavailableUnavailableUnavailable
Current liabilities$1.97M$1.02M$715.96K$853.22K$396.48K
Total equity incl. NCI-$1.93M-$950.79K-$121.65K-$449.11K$301.96K
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$537.45K$272.32K$487.79K$501.73K$396.48K

Cash flow

Vicapsys Life Sciences, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2023-12-312022-12-312021-12-312020-12-312019-12-31
Operating cash flow-$417.52K-$238.20K-$443.97K-$262.90K-$970.26K
Capital expendituresUnavailableUnavailableUnavailableUnavailableUnavailable
Investing cash flowUnavailableUnavailable$100.00KUnavailableUnavailable
Financing cash flow$412.85K$35.00K$560.00KUnavailable$1.15M
Net change in cash-$4.68K-$203.20K$216.03K-$262.90K$177.84K
Stock-based compensation$20.70K$105.65K$4.33K$14.78K$118.65K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

Vicapsys Life Sciences, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2023-12-312022-12-312021-12-312020-12-312019-12-31
Free cash flowUnavailableUnavailableUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio0.02x0.07x0.31x0.00x0.67x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open VICP in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2025-01-10View SEC filing
10-Q · Filed 2025-01-10View SEC filing
10-Q · Filed 2025-01-10View SEC filing
10-K · Filed 2024-10-21View SEC filing
10-Q · Filed 2023-11-14View SEC filing
10-Q · Filed 2023-08-14View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.